Ligand Pharmaceuticals Incorporated announced today that the U.S. FDA has granted accelerated approval of GlaxoSmithKline's PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. PROMACTA is the first oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic ITP.
The details can be read here.
No comments:
Post a Comment